Drug | Effect of Interaction |
---|---|
Gold salts | Increased risk of blood dyscrasias |
Methotrexate | Increased risk of bone marrow suppression |
Dapsone | Folate antagonists may increase the likelihood of adverse hematologic reactions (e.g., agranulocytosis, anaemia) |
Carvedilol | Possible for increased serum concentration of the S-carvedilol enantiomer |
Phenothiazines | Anti-malarial agents may increase the serum concentration |
Fesoterodine | Serum concentrations of the active metabolite may be increased |
Nebivolol | Serum concentration may be increased |
Zidovudine, abacavir, lamivudine | Increased risk of bone marrow suppression |
Tamoxifen | Metabolism of Tamoxifen to the active metabolites may be decreased |
Lorazepam | Increases risk of elevated liver function tests |
Codeine | CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine, diminishing its therapeutic effect |
Tramadol | CYP2D6 inhibitors may prevent the metabolic conversion to the active metabolite, diminishing its therapeutic effect |
Antacids | Reduce the absorption of pyrimethamine (decreased bioavailability) |